Arcturus Therapeutics (NASDAQ:ARCT) reported quarterly losses of $(0.84) per share which beat the analyst consensus estimate of $(1.00) by 16 percent. This is a 147.06 percent decrease over losses of $(0.34) per share from the same period last year. The company reported quarterly sales of $2.959 million which missed the analyst consensus estimate of $3.199 million by 7.50 percent. This is a 89.54 percent decrease over sales of $28.301 million the same period last year.